Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein

被引:50
作者
Gardner, Alison A. [1 ]
Reichert, Ethan C. [1 ]
Topham, Matthew K. [1 ,2 ]
Stafforini, Diana M. [1 ,2 ]
机构
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA
关键词
D O I
10.1074/jbc.M802394200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The plasma form of platelet-activating factor (PAF) acetylhydrolase (PAF-AH), also known as lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inactivates potent lipid messengers such as PAF and modified phospholipids generated in settings of oxidant stress. In humans, PAF-AH circulates in blood in fully active form and associates with high and low density lipoproteins (HDL and LDL). Several studies suggest that the location of PAF-AH affects both the catalytic efficiency and the function of the enzyme in vivo. The distribution of PAF-AH among lipoproteins varies widely among mammals. Here, we report that mouse and human PAF-AHs associate with human HDL particles of different density. We made use of this observation in the development of a binding assay to identify domains required for association of human PAF-AH with human HDL. Sequence comparisons among species combined with domain-swapping and site-directed mutagenesis studies led us to the identification of C-terminal residues necessary for the association of human PAF-AH with human HDL. Interestingly, the region identified is not conserved among PAF-AHs, suggesting that PAF-AH interacts with HDL particles in a manner that is unique to each species. These findings contribute to our understanding of the mechanisms responsible for association of human PAF-AH with HDL and may facilitate future studies aimed at precisely determining the function of PAF-AH in each lipoprotein particle.
引用
收藏
页码:17099 / 17106
页数:8
相关论文
共 62 条
[1]   The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients [J].
Allison, Matthew A. ;
Denenberg, Julie O. ;
Nelson, Jeanenne J. ;
Natarajan, Loki ;
Criqui, Michael H. .
JOURNAL OF VASCULAR SURGERY, 2007, 46 (03) :500-506
[2]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[3]  
Bayes M, 2006, Methods Find Exp Clin Pharmacol, V28, P451
[4]   Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia [J].
Bell, R ;
Collier, DA ;
Rice, SQJ ;
Roberts, GW ;
MacPhee, CH ;
Kerwin, RW ;
Price, J ;
Gloger, IS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 241 (03) :630-635
[5]   The discoverv of SB-435495:: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man [J].
Blackie, JA ;
Bloomer, JC ;
Brown, MJB ;
Cheng, HY ;
Elliott, RL ;
Hammond, B ;
Hickey, DMB ;
Ife, RJ ;
Leach, CA ;
Lewis, VA ;
Macphee, CH ;
Milliner, KJ ;
Moores, KE ;
Pinto, IL ;
Smith, SA ;
Stansfield, IG ;
Stanway, SJ ;
Taylor, MA ;
Theobald, CJ ;
Whittaker, CM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (18) :2603-2606
[6]   A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women [J].
Blake, GJ ;
Dada, N ;
Fox, JC ;
Manson, JE ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1302-1306
[7]   Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].
Brilakis, ES ;
McConnell, JP ;
Lennon, RJ ;
Elesber, AA ;
Meyer, JG ;
Berger, PB .
EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144
[8]   Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages [J].
Carpenter, KLH ;
Dennis, IF ;
Challis, IR ;
Osborn, DP ;
Macphee, CH ;
Leake, DS ;
Arends, MJ ;
Mitchinson, MJ .
FEBS LETTERS, 2001, 505 (03) :357-363
[9]   High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients [J].
Corsetti, JP ;
Rainwater, DL ;
Moss, AJ ;
Zareba, W ;
Sparks, CE .
CLINICAL CHEMISTRY, 2006, 52 (07) :1331-1338
[10]  
De Geest B, 2000, ARTERIOSCL THROM VAS, V20, pE68